Clinical trials testing HER-2-directed CAR T therapy in children with CNS tumors, EGFR-directed CARs for children and AYAs with CNS tumors and B7-H3-specific CAR Ts in patients with DIPG/DMG or refractory pediatric CNS tumors are ongoing (NCT03500991, NCT03638167 and NCT04185038). This evidence concerns the gene CD276 and central nervous system neoplasm.